Okyo Pharma Share Discussion Threads

[spurs90] 23/7/2020 07:16

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 07:15

IQ-AI LIMITED

("IQ-AI" or the "Company")



Initiation of IB Stroke Project



IQ-AI announces that a series of new technology initiatives are being launched that will form the backbone for the Company's new products as well as enhancements to existing products during calendar 2020. These advancements are substantially derived from the progress being made with IQ-AI's previously announced Gadolinium free product initiative.



Most notable of these initiatives is a project which we expect to complete in the final quarter of 2020, to leverage our existing algorithms to create an 'IB Stroke' package. One of the unique features of Imaging Biometrics' (IB) portfolio of brain focused products is their ability to accurately map and quantify blood flow in the brain. IB already offers a unique biopsy-validated diagnostic imaging platform to neuroradiologists for assessing brain tumors and monitoring their response to treatment. IB also offers all the metrics found to be most valuable for the evaluation of stroke and response to therapies. For example, IB's proven perfusion and diffusion maps will be used to generate the perfusion-diffusion mismatch (DPM) which typically represents ischemic penumbra, or the area of viable tissue at risk. IB will leverage its proven ability of efficiently translating novel developments into routine clinical use, to create an automated and streamlined processing application for clinician's use.



There are two principal forms of stroke, hemorrhagic stroke and ischemic stroke. Hemorrhagic stroke results from ruptured blood vessels, ischemic stroke results from blocked blood vessels. Both have the effect of denying brain tissue sufficient blood flow, nutrients and oxygen to maintain its viability. The ability of IB's suite of products to accurately track regional blood volume can be used to diagnose and project outcomes for stroke victims. With respect to MR processing, the commonly accepted pre-load dose of gadolinium could also be avoided with this product which is consistent with our longer-term goal of reducing and eliminating gadolinium-based contrast agents. Eliminating this pre-load dose of contrast agent for stroke assessment could potentially save valuable time which is absolutely critical for stroke patients.



In the USA, the Center for Disease Control (CDC) reports that annually 795,000 people have a stroke. Of these, 610,000 are new strokes and 87% are ischemic strokes, the remainder being hemorrhagic strokes. According to the CDC, "Stroke costs the United States an estimated $34 billion each year.1 This total includes the cost of health care services, medicines to treat stroke, and missed days of work," and "Stroke is a leading cause of serious long-term disability. Stroke reduces mobility in more than half of stroke survivors age 65 and over."¹



David Smith, COO of IQ-AI Ltd. commented "This initiative grew out of the solid progress we are making on our gadolinium free project and represents an area that is 30 times the size of that product opportunity. Further, it uses the diagnostic imaging techniques that are already in our FDA cleared IB suite of brain tumor focused products."

[spurs90] 23/7/2020 07:13

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.



Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.



Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.



IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:12

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[hope67] 21/7/2020 21:18

Terry. hxxps://t.me/joinchat/HkgNOBegu0f_uURKbm3GNw

[stenick] 21/7/2020 09:50

Accustem ltd registered at companies house, easy to become a plc. I’d be careful.IMO

[terry508] 21/7/2020 08:14

Is there a link to Telegram please

[albert arthur] 20/7/2020 20:01

You might have just hit the jackpot..

[kasspass] 20/7/2020 19:39

Can't wait for it to fly to b honest.. I ve been holding this from the days when it was a mining company.

[stg8123] 20/7/2020 15:43

You will soon see my friend

[theprid1986] 20/7/2020 15:33

New home for stemprinter ?sp about to fly when the cats out the bag mate

[kasspass] 20/7/2020 15:22

What's going on here? I know some directors sit on bod of tiziana (tips) which is on an upward trend now.

[volsung] 15/7/2020 10:55

Bought a few

[bibs] 15/7/2020 10:47

Glad I did my research back end of last year.Market for their product is enormous!

[jimsyone] 04/7/2020 11:54

Goldman Sachs - Berenberg - Peel Hunt - Liberum - Cannaccord give the top fund managers picks

[faraweigh2] 04/7/2020 11:00

Hey, super dave!Cash raised at 0.4 and where's the share price now? Just goes to prove all the scaremongering posting you churn out is ill considered drivel.Shame on you!

[bibs] 02/7/2020 15:44

For whoever ticked down, just checked my HL account.29 May paid 1.4999...From memory they showed up as 1.5 trades. Was only able to purchase small lots.GLA

[bibs] 02/7/2020 13:59

I bought at 1.49p a few weeks ago.Didn't think it would keep going like this??

[swerves1] 04/6/2020 20:17

Dave4545 - a foolish claim....as huge price rise since!

[justaman] 29/5/2020 08:37

HEMO at the bottom, about to flip and news due with majors.